Literature DB >> 29864032

Pharmacokinetic and pharmacodynamic analysis of d-amphetamine in an attention task in rodents.

Jonathan M Slezak1, Melanie Mueller2, George A Ricaurte2, Jonathan L Katz3.   

Abstract

Amphetamine is a common therapeutic agent for alleviating the core symptoms associated with attention-deficit hyperactivity disorder (ADHD) in children and adults. The current study used a translational model of attention, the five-choice serial reaction time (5-CSRT) procedure with rats, to examine the time-course effects of d-amphetamine. Effects of different dosages of d-amphetamine were related to drug-plasma concentrations, fashioned after comprehensive pharmacokinetic/pharmacodynamic assessments that have been employed in clinical investigations. We sought to determine whether acute drug-plasma concentrations that enhance performance in the 5-CSRT procedure are similar to those found to be therapeutic in patients diagnosed with ADHD. Results from the pharmacokinetic/pharmacodynamic assessment indicate that d-amphetamine plasma concentrations associated with improved performance on the 5-CSRT procedure overlap with those that have been reported to be therapeutic in clinical trials. The current findings suggest that the 5-CSRT procedure may be a useful preclinical model for predicting the utility of novel ADHD therapeutics and their effective concentrations.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29864032      PMCID: PMC6076339          DOI: 10.1097/FBP.0000000000000409

Source DB:  PubMed          Journal:  Behav Pharmacol        ISSN: 0955-8810            Impact factor:   2.293


  29 in total

1.  Methylphenidate preferentially increases catecholamine neurotransmission within the prefrontal cortex at low doses that enhance cognitive function.

Authors:  Craig W Berridge; David M Devilbiss; Matthew E Andrzejewski; Amy F T Arnsten; Ann E Kelley; Brooke Schmeichel; Christina Hamilton; Robert C Spencer
Journal:  Biol Psychiatry       Date:  2006-06-23       Impact factor: 13.382

2.  Amphetamine treatment similar to that used in the treatment of adult attention-deficit/hyperactivity disorder damages dopaminergic nerve endings in the striatum of adult nonhuman primates.

Authors:  George A Ricaurte; Annis O Mechan; Jie Yuan; George Hatzidimitriou; Tao Xie; Andrew H Mayne; Una D McCann
Journal:  J Pharmacol Exp Ther       Date:  2005-07-13       Impact factor: 4.030

Review 3.  Effects of stimulants on the continuous performance test (CPT): implications for CPT use and interpretation.

Authors:  C A Riccio; J J Waldrop; C R Reynolds; P Lowe
Journal:  J Neuropsychiatry Clin Neurosci       Date:  2001       Impact factor: 2.198

Review 4.  Pharmacokinetic and pharmacodynamic properties of stimulants: implications for the design of new treatments for ADHD.

Authors:  J M Swanson; N D Volkow
Journal:  Behav Brain Res       Date:  2002-03-10       Impact factor: 3.332

5.  Sub-optimal performance in the 5-choice serial reaction time task in rats was sensitive to methylphenidate, atomoxetine and d-amphetamine, but unaffected by the COMT inhibitor tolcapone.

Authors:  Neil E Paterson; Jennifer Ricciardi; Caitlin Wetzler; Taleen Hanania
Journal:  Neurosci Res       Date:  2010-10-08       Impact factor: 3.304

6.  Adult outcome of attention-deficit/hyperactivity disorder: a controlled 16-year follow-up study.

Authors:  Joseph Biederman; Carter R Petty; K Yvonne Woodworth; Alexandra Lomedico; Laran L Hyder; Stephen V Faraone
Journal:  J Clin Psychiatry       Date:  2012-07       Impact factor: 4.384

7.  An influence of delayed reinforcement on the effectiveness of psychostimulants to enhance indices of attention under a five-choice serial reaction time procedure in male rats.

Authors:  Jonathan M Slezak; Jonathan L Katz
Journal:  Exp Clin Psychopharmacol       Date:  2013-10       Impact factor: 3.157

8.  Exposure of adolescent rats to oral methylphenidate: preferential effects on extracellular norepinephrine and absence of sensitization and cross-sensitization to methamphetamine.

Authors:  Ronald Kuczenski; David S Segal
Journal:  J Neurosci       Date:  2002-08-15       Impact factor: 6.167

9.  Differential effects of psychomotor stimulants on attentional performance in rats: nicotine, amphetamine, caffeine and methylphenidate.

Authors:  L Bizarro; S Patel; C Murtagh; I P Stolerman
Journal:  Behav Pharmacol       Date:  2004-05       Impact factor: 2.293

10.  Sensitivity of the five-choice serial reaction time task to the effects of various psychotropic drugs in Sprague-Dawley rats.

Authors:  Tracie A Paine; Hilarie C Tomasiewicz; Kehong Zhang; William A Carlezon
Journal:  Biol Psychiatry       Date:  2007-03-07       Impact factor: 13.382

View more
  5 in total

1.  Vigilance demand and the effects of stimulant drugs in a five-choice reaction-time procedure in mice.

Authors:  Jonathan L Katz; Stephen J Kohut; Paul Soto
Journal:  Behav Pharmacol       Date:  2018-12       Impact factor: 2.293

2.  Investigating sex differences and the effect of drug exposure order in the sensory reward-enhancing effects of nicotine and d-amphetamine alone and in combination.

Authors:  Kathleen R McNealy; Sydney D Houser; Scott T Barrett; Rick A Bevins
Journal:  Neuropharmacology       Date:  2021-10-19       Impact factor: 5.250

3.  The Effects of Drug Treatments for ADHD in Measures of Cognitive Performance.

Authors:  Guy A Higgins; Leo B Silenieks
Journal:  Curr Top Behav Neurosci       Date:  2022

4.  Reward-enhancing effects of d-amphetamine and its interactions with nicotine were greater in female rats and persisted across schedules of reinforcement.

Authors:  Kathleen R McNealy; Margaret E Ramsay; Scott T Barrett; Rick A Bevins
Journal:  Behav Pharmacol       Date:  2021-08-01       Impact factor: 2.277

5.  Altered metabolic pathways elucidated via untargeted in vivo toxicometabolomics in rat urine and plasma samples collected after controlled application of a human equivalent amphetamine dose.

Authors:  Selina Hemmer; Lea Wagmann; Markus R Meyer
Journal:  Arch Toxicol       Date:  2021-08-19       Impact factor: 5.153

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.